Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


07.01.2019

2 Ann Oncol
2 Ann Thorac Surg
1 Br J Cancer
4 Cancer Sci
1 Clin Nucl Med
1 Eur Respir J
1 J Thorac Oncol
1 Mol Carcinog
2 Oncologist
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Oncol

  1. WANG Y, Jiang T, Qin Z, Jiang J, et al
    HER2 exon 20 insertions in Non-Small Cell Lung Cancer are Sensitive to the Irreversible Pan-HER Receptor Tyrosine Kinase Inhibitor Pyrotinib.
    Ann Oncol. 2018 Dec 31. pii: 5267836. doi: 10.1093.
    PubMed     Text format     Abstract available

  2. WU YL, Planchard D, Lu S, Sun H, et al
    Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer; a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.
    Ann Oncol. 2018 Dec 28. pii: 5265324. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Thorac Surg

  3. SAKAGUCHI Y, Matsumoto K
    Lobectomy for lung cancer with congenital pericardial defect.
    Ann Thorac Surg. 2018 Dec 31. pii: S0003-4975(18)31865.
    PubMed     Text format     Abstract available

  4. SMELTZER MP, Faris NR, Ray MA, Fehnel C, et al
    Survival before and after direct surgical quality feedback in a population-based lung cancer cohort.
    Ann Thorac Surg. 2018 Dec 27. pii: S0003-4975(18)31859.
    PubMed     Text format     Abstract available


    Br J Cancer

  5. GADGEEL S, Shaw AT, Barlesi F, Crino L, et al
    Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
    Br J Cancer. 2018;118:38-42.
    PubMed     Text format     Abstract available


    Cancer Sci

  6. GU MM, Gao D, Yao PA, Yu L, et al
    p53-inducible gene 3 promotes cell migration and invasion by activating the FAK/Src pathway in lung adenocarcinoma.
    Cancer Sci. 2018;109:3783-3793.
    PubMed     Text format     Abstract available

  7. IWAMA E, Sakai K, Azuma K, Harada D, et al
    Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing.
    Cancer Sci. 2018;109:3921-3933.
    PubMed     Text format     Abstract available

  8. LIAO M, Liu Q, Li B, Liao W, et al
    A group of long noncoding RNAs identified by data mining can predict the prognosis of lung adenocarcinoma.
    Cancer Sci. 2018;109:4033-4044.
    PubMed     Text format     Abstract available

  9. PAN H, Peng Z, Lin J, Ren X, et al
    Forkhead box C1 boosts triple-negative breast cancer metastasis through activating the transcription of chemokine receptor-4.
    Cancer Sci. 2018;109:3794-3804.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  10. SENIARAY N, Verma R, Belho ES, Mahajan H, et al
    Incidental Detection of Skeletal Metastases on 99mTc-DTPA Renography.
    Clin Nucl Med. 2018;43:918-920.
    PubMed     Text format     Abstract available


    Eur Respir J

  11. UGUEN M, Dewitte JD, Lodde B, Marcorelles P, et al
    Asbestos-related lung cancers are rarely associated with ALK, ROS1 and RET rearrangements.
    Eur Respir J. 2018;51.
    PubMed     Text format    


    J Thorac Oncol

  12. PACHECO JM, Gao D, Smith D, Purcell WT, et al
    Natural history and factors associated with overall survival in stage IV ALK rearranged non-small-cell lung cancer.
    J Thorac Oncol. 2018 Dec 29. pii: S1556-0864(18)33533.
    PubMed     Text format     Abstract available


    Mol Carcinog

  13. ZHANG X, Han S, Zhou H, Cai L, et al
    TIMM50 promotes tumor progression via ERK signaling and predicts poor prognosis of non-small cell lung cancer patients.
    Mol Carcinog. 2019 Jan 3. doi: 10.1002/mc.22969.
    PubMed     Text format     Abstract available


    Oncologist

  14. PATIL PD, Shapiro M, Hashemi Sadraei N, Pennell NA, et al
    An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer.
    Oncologist. 2019 Jan 2. pii: theoncologist.2018-0857.
    PubMed     Text format     Abstract available

  15. CHALMERS A, Cannon L, Akerley W
    Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib.
    Oncologist. 2018 Dec 31. pii: theoncologist.2018-0296.
    PubMed     Text format     Abstract available


    PLoS One

  16. LIU T, Chen Z, Dang J, Li G, et al
    The role of surgery in stage I to III small cell lung cancer: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0210001.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: